Risperidone long-acting injectable was found to be effective in protecting from any mood/manic symptom compared to placebo , but not from depressive recurrences .
Add-on or monotherapy paliperidone palmitate in SAD patients  protected from psychotic , depressive , and manic symptoms .
In patients with BD-I with a manic episode at study enrolment , aripiprazole monohydrate significantly delayed time to recurrence of manic episodes without inducing depressive episodes .
LAIs  are effective and well-tolerated maintenance treatments for BD and SAD .
They showed better efficacy in preventing mania than depression .
LAIs may be first-line for BD-I and SAD patients with a manic predominant polarity and with non-adherence problems
Long-Acting Injectable Antipsychotics ( LAIs ) are used to overcome non-compliance in psychoses , mainly schizophrenia spectrum disorders .
We aim ed to summarize available evidence of studies comparing the efficacy of LAIs to placebo or oral medications for Bipolar Disorder ( BD ) and /or Schizoaffective Disorder ( SAD ) .
Efficacy and Safety of Aripiprazole Once-Monthly in the Maintenance Treatment of Bipolar I Disorder: A Double-Blind, Placebo-Controlled, 52-Week Randomized Withdrawal Study.
OBJECTIVE To evaluate efficacy , safety , and tolerability of long-acting injectable antipsychotic aripiprazole once-monthly 400 mg ( AOM 400 ) as maintenance treatment for bipolar I disorder ( BP-I ) . METHODS In a double-blind , placebo-controlled , 52-week r and omized withdrawal study conducted from August 2012 to April 2016 , patients with a DSM-IV-TR diagnosis of BP-I currently experiencing a manic episode were stabilized sequentially on oral aripiprazole and AOM 400 and then r and omized to AOM 400 or placebo . The primary end point was time from r and omization to recurrence of any mood episode . Other end points included proportion of patients with recurrence of any mood episode and recurrence by mood episode type . RESULTS Of 266 r and omized patients , 64 ( 48.1 % ) of 133 in the AOM 400 group and 38 ( 28.6 % ) of 133 in the placebo group completed the study .  AOM 400 significantly delayed the time to recurrence of any mood episode compared with placebo ( hazard ratio : 0.45 ; 95 % CI , 0.30 to 0.68 ; P < .0001 ) . Significantly fewer patients ( P < .0001 ) experienced recurrence of any mood episode with AOM 400 ( 35/132 ; 26.5 % ) compared with placebo ( 68/133 ; 51.1 % ) , with the effects observed predominantly on manic episodes ( P < .0001 ) . Patients were not depressed at study entry , and between-group differences in depressive episodes were not significant ( P < .864 ) . The treatment-emergent adverse events ( incidence > 5 % ) that were reported at higher rates with AOM 400 than placebo were weight increase , akathisia , insomnia , and anxiety . CONCLUSIONS AOM 400 delayed the time to and reduced the rate of recurrence of mood episodes and was generally safe and well tolerated . These findings support the use of AOM 400 for maintenance treatment of BP-I. TRIAL REGISTRATION Clinical Trials.gov identifier : NCT01567527
Risperidone long-acting injectable was found to be effective in protecting from any mood/manic symptom compared to placebo , but not from depressive recurrences .
Add-on or monotherapy paliperidone palmitate in SAD patients  protected from psychotic , depressive , and manic symptoms .
In patients with BD-I with a manic episode at study enrolment , aripiprazole monohydrate significantly delayed time to recurrence of manic episodes without inducing depressive episodes .
LAIs  are effective and well-tolerated maintenance treatments for BD and SAD .
They showed better efficacy in preventing mania than depression .
LAIs may be first-line for BD-I and SAD patients with a manic predominant polarity and with non-adherence problems
Long-Acting Injectable Antipsychotics ( LAIs ) are used to overcome non-compliance in psychoses , mainly schizophrenia spectrum disorders .
We aim ed to summarize available evidence of studies comparing the efficacy of LAIs to placebo or oral medications for Bipolar Disorder ( BD ) and /or Schizoaffective Disorder ( SAD ) .